newsfilter
← Latest News
Business Wire·

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Low rates of treatment-related adverse events (42%) and dose interruptions (1.6%) Emerging detalimogene profile supports potential first line use in patients with high-risk, BCG-unresponsive non-muscle invasive